A new report says that Big Pharma may be throwing away billions of dollars on ad campaigns in the United States in an effort to promote a drug directly with the public.
In 1997, the United States lifted a ban on prescription-drug ads that are pitched directly at the public rather than at doctors or other health professionals.
Chemotherapy Drugs
Chemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body.
Advertisement
The change prompted pharmaceutical companies to invest heavily in retail advertising, and annual spending in this sector now averages more than five billion dollars (four billion euros).
Advocates of direct-to-public drug advertising say it raises awareness and encourages the treatment of neglected conditions.
Critics counter that it artificially drives up demand for expensive novel drugs that have not been tested over the long haul.
![Free Anti-retroviral Treatment for HIV-positive Ivorians]( "Free Anti-retroviral Treatment for HIV-positive Ivorians")
Ivorians with HIV/AIDS can now get free anti-retroviral treatment in public health centers with foreign funders picking up much of the tab, according to a decree of which AFP obtained a copy Friday.
Both sides, though, have assumed that the marketing technique works -- but the new study suggests they have got it flat wrong.
"People tend to think that if direct-to-consumer advertising wasn't effective, Pharma wouldn't be doing it," said Harvard Medical School professor Stephen Soumerai, who led the investigation.
"But as it turns out, decisions to market directly to consumers are based on scant data."
Even when sales increase, it has been nearly impossible to isolate the impact of targeting consumers from, say, marketing campaigns directed at doctors and health professionals.
Ideally, one would want to compare two otherwise identical populations before and after one of them is exposed to direct-to-consumer ads for certain drugs in order to measure the difference.
In the United States that is not possible, so Soumerai came up with a clever idea: Canada.
Direct-to-consumer ads for prescription drugs are illegal north of the US border, but English-speaking Canadians are still massively exposed to pharma advertising on American television and radio, and in US magazines.
Their French-speaking neighbours in the Canadian province of Quebec, however, are not, which provided the investigators with a useful group for making a comparison.
The study focused on three drugs: Enbrel, for arthritis; Nasonex, for allergies; and Zelnorm, for irritable bowel syndrome.
All three had been on the market in both countries for at least one year before the direct-to-consumer campaigns began in the United States.
The question was simple: once the ads kicked in, did sales increase more quickly in English-speaking Canada than in Quebec?
Based on data from a registry of 2,700 pharmacies, the answer for the first two drugs was a clear "no", while for the third drug, sales initially leapt in the Canadian anglophone market but then fell back.
The study was published online on Tuesday by the British Medical Journal (BMJ).
Sales of Zelnorm initially jumped 40 percent, but within a couple of years prescription rates in both groups were the same again.
Given that Zelnorm was the only drug available for that syndrome, it might have sold as well without the direct-to-consumer ads.
Soumerai thinks the ads failed because the process of buying prescription drugs is not as easy or spontaneous as buying over-the-counter medication such as aspirin.
A person has to see an ad, get motivated, contact their doctor, show up for an appointment, communicate both the condition and the drug, convince the doctor to prescribe it, and then actually fill the prescription, which is also likely to carry an out-of-pocket cost, he explained.
The United States is one of only two countries in the world -- along with New Zealand -- where direct-to-consumer ads for prescription medication is legal.
In March 2007, Zelnorm was pulled from the market due to concerns about increased risk of heart attack and stroke.
Source: AFP
RAS/M
Critics counter that it artificially drives up demand for expensive novel drugs that have not been tested over the long haul.
Free Anti-retroviral Treatment for HIV-positive Ivorians
Ivorians with HIV/AIDS can now get free anti-retroviral treatment in public health centers with foreign funders picking up much of the tab, according to a decree of which AFP obtained a copy Friday.
Advertisement
Both sides, though, have assumed that the marketing technique works -- but the new study suggests they have got it flat wrong.
"People tend to think that if direct-to-consumer advertising wasn't effective, Pharma wouldn't be doing it," said Harvard Medical School professor Stephen Soumerai, who led the investigation.
"But as it turns out, decisions to market directly to consumers are based on scant data."
Even when sales increase, it has been nearly impossible to isolate the impact of targeting consumers from, say, marketing campaigns directed at doctors and health professionals.
Ideally, one would want to compare two otherwise identical populations before and after one of them is exposed to direct-to-consumer ads for certain drugs in order to measure the difference.
In the United States that is not possible, so Soumerai came up with a clever idea: Canada.
Direct-to-consumer ads for prescription drugs are illegal north of the US border, but English-speaking Canadians are still massively exposed to pharma advertising on American television and radio, and in US magazines.
Their French-speaking neighbours in the Canadian province of Quebec, however, are not, which provided the investigators with a useful group for making a comparison.
The study focused on three drugs: Enbrel, for arthritis; Nasonex, for allergies; and Zelnorm, for irritable bowel syndrome.
All three had been on the market in both countries for at least one year before the direct-to-consumer campaigns began in the United States.
The question was simple: once the ads kicked in, did sales increase more quickly in English-speaking Canada than in Quebec?
Based on data from a registry of 2,700 pharmacies, the answer for the first two drugs was a clear "no", while for the third drug, sales initially leapt in the Canadian anglophone market but then fell back.
The study was published online on Tuesday by the British Medical Journal (BMJ).
Sales of Zelnorm initially jumped 40 percent, but within a couple of years prescription rates in both groups were the same again.
Given that Zelnorm was the only drug available for that syndrome, it might have sold as well without the direct-to-consumer ads.
Soumerai thinks the ads failed because the process of buying prescription drugs is not as easy or spontaneous as buying over-the-counter medication such as aspirin.
A person has to see an ad, get motivated, contact their doctor, show up for an appointment, communicate both the condition and the drug, convince the doctor to prescribe it, and then actually fill the prescription, which is also likely to carry an out-of-pocket cost, he explained.
The United States is one of only two countries in the world -- along with New Zealand -- where direct-to-consumer ads for prescription medication is legal.
In March 2007, Zelnorm was pulled from the market due to concerns about increased risk of heart attack and stroke.
Source: AFP
RAS/M
Beware of Possible Botox Side Effects: European Agency
Months after US authorities sounded the alarm, European officials are warning of dangerous possible side effects from the wrinkle-smoothing injection Botox, according to a German news report.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.